NASDAQ:NLTX Neoleukin Therapeutics (NLTX) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free NLTX Stock Alerts $29.96 +0.09 (+0.30%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$29.88▼$31.5250-Day Range$13.96▼$50.9052-Week Range$2.03▼$14.36Volume47,839 shsAverage Volume50,104 shsMarket Capitalization$281.56 millionP/E RatioN/ADividend YieldN/APrice Target$30.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Neoleukin Therapeutics alerts: Email Address Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. About Neoleukin Therapeutics Stock (NASDAQ:NLTX)Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Read More NLTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NLTX Stock News HeadlinesDecember 20, 2023 | finance.yahoo.comIs Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?December 15, 2023 | finance.yahoo.comNeoleukin Therapeutics Announces 1-for-4 Reverse Stock SplitApril 26, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.December 4, 2023 | benzinga.comNeoleukin Therapeutics Stock (NASDAQ:NLTX) Dividends: History, Yield and DatesOctober 5, 2023 | markets.businessinsider.comPre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…September 26, 2023 | finanznachrichten.deNeoleukin Therapeutics, Inc.: Neoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitSeptember 22, 2023 | finance.yahoo.comNeoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitAugust 18, 2023 | benzinga.comNeoleukin Therapeutics Recent Insider ActivityApril 26, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.August 18, 2023 | finance.yahoo.comBAKER BROS. ADVISORS LP Reduces Stake in Neoleukin Therapeutics IncAugust 8, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, CCF, NLTX, SCUAugust 1, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AJX, DEN, FREQ, NLTXJuly 28, 2023 | finance.yahoo.comRedmile Group, LLC Boosts Stake in Neoleukin Therapeutics IncJuly 26, 2023 | benzinga.comMoore Kuehn Encourages AMNB, SCU, NLTX, and PRDS Investors to Contact Law FirmJuly 24, 2023 | 247wallst.comBaker Bros. Advisors Now Owns 19.99% of Neoleukin TherapeuticsJuly 19, 2023 | markets.businessinsider.comNeurogene, Neoleukin Announce Planned MergerJuly 18, 2023 | msn.comUniv. of Washington spinout Neoleukin Therapeutics merging with New York City startupJuly 18, 2023 | finanznachrichten.deNeoleukin Therapeutics, Inc.: Neurogene and Neoleukin Announce Definitive Merger AgreementJuly 18, 2023 | benzinga.comNeoleukin Therapeutics To Merge With Neurogene: Creates Biotech Firm Focused On Genetic Medicines For Neurological DiseasesJuly 18, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DEN, NLTX, FREQJuly 18, 2023 | msn.comNeoleukin jumps 7% on Neurogene mergerJuly 18, 2023 | marketwatch.comNeoleukin Therapeutics Shares Rise Premarket on Reverse Merger Deal >NLTXJuly 18, 2023 | technews.tmcnet.comNLTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Neoleukin Therapeutics, Inc. Is Fair to ShareholdersJuly 18, 2023 | finance.yahoo.comNeurogene and Neoleukin Announce Definitive Merger AgreementMay 23, 2023 | finance.yahoo.comBiomed Industries, Inc. Offers to acquire Neoleukin Therapeutics, Inc. (NASDAQ:NLTX)May 9, 2023 | markets.businessinsider.comMizuho Securities Reaffirms Their Hold Rating on Neoleukin Therapeutics (NLTX)April 7, 2023 | bizjournals.comNeoleukin Therapeutics promotes general counsel to interim CEOSee More Headlines Receive NLTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neoleukin Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NLTX CUSIPN/A CIK1404644 Webwww.neoleukin.com Phone(866) 245-0312Fax778-331-4486Employees7Year FoundedN/APrice Target and Rating Average Stock Price Target$30.00 High Stock Price Target$30.00 Low Stock Price Target$30.00 Potential Upside/Downside+0.4%Consensus Rating Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($3.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,560,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-37.22% Return on Assets-30.91% Debt Debt-to-Equity RatioN/A Current Ratio15.33 Quick Ratio15.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.08 per share Price / Book2.70Miscellaneous Outstanding Shares9,398,000Free Float9,250,000Market Cap$280.72 million OptionableOptionable Beta1.11 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMs. Donna M. Cochener-Metcalfe J.D. (Age 48)General Counsel, Interim CEO & Corporate Secretary Comp: $403.75kDr. David Baker M.D.Ph.D., Co-FounderMr. Sean Michael Smith (Age 37)Interim Chief Financial Officer Key CompetitorsKamadaNASDAQ:KMDAErascaNASDAQ:ERASVerrica PharmaceuticalsNASDAQ:VRCAContineum TherapeuticsNASDAQ:CTNMRenovaroNASDAQ:RENBView All CompetitorsInsidersBros. Advisors Lp BakerBought 8,347 shares on 8/17/2023Total: $115,188.60 ($13.80/share)Bros. Advisors Lp BakerBought 94,440 shares on 8/15/2023Total: $1.19 M ($12.60/share)Sean Michael SmithSold 66 sharesTotal: $818.40 ($12.40/share)View All Insider Transactions NLTX Stock Analysis - Frequently Asked Questions What is Neoleukin Therapeutics' stock price target for 2024? 0 Wall Street analysts have issued 1 year price targets for Neoleukin Therapeutics' stock. Their NLTX share price targets range from $30.00 to $30.00. On average, they anticipate the company's share price to reach $30.00 in the next year. This suggests a possible upside of 0.4% from the stock's current price. View analysts price targets for NLTX or view top-rated stocks among Wall Street analysts. How have NLTX shares performed in 2024? Neoleukin Therapeutics' stock was trading at $19.38 at the beginning of the year. Since then, NLTX stock has increased by 54.1% and is now trading at $29.87. View the best growth stocks for 2024 here. How were Neoleukin Therapeutics' earnings last quarter? Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($5.60) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($5.60). When did Neoleukin Therapeutics' stock split? Neoleukin Therapeutics shares reverse split on the morning of Tuesday, December 19th 2023. The 1-4 reverse split was announced on Tuesday, December 19th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 19th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. What other stocks do shareholders of Neoleukin Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neoleukin Therapeutics investors own include Alibaba Group (BABA), Cisco Systems (CSCO), Pfizer (PFE), RTX (RTX), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), CVS Health (CVS), Fulcrum Therapeutics (FULC) and Home Depot (HD). How do I buy shares of Neoleukin Therapeutics? Shares of NLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NLTX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neoleukin Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
